BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) and Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.
Profitability
This table compares BioMarin Pharmaceutical and Arbutus Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioMarin Pharmaceutical | -0.52% | 5.58% | 3.51% |
| Arbutus Biopharma | 121.17% | 129.12% | 89.26% |
Insider and Institutional Ownership
98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares BioMarin Pharmaceutical and Arbutus Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioMarin Pharmaceutical | $3.66 billion | 3.20 | $348.90 million | ($0.10) | -604.10 |
| Arbutus Biopharma | $14.08 million | 43.77 | -$33.50 million | $1.13 | 3.56 |
BioMarin Pharmaceutical has higher revenue and earnings than Arbutus Biopharma. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
BioMarin Pharmaceutical has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for BioMarin Pharmaceutical and Arbutus Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioMarin Pharmaceutical | 1 | 6 | 15 | 3 | 2.80 |
| Arbutus Biopharma | 0 | 1 | 0 | 0 | 2.00 |
BioMarin Pharmaceutical presently has a consensus price target of $87.22, suggesting a potential upside of 44.38%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe BioMarin Pharmaceutical is more favorable than Arbutus Biopharma.
Summary
Arbutus Biopharma beats BioMarin Pharmaceutical on 8 of the 15 factors compared between the two stocks.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
About Arbutus Biopharma
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection. Its research programs include RNA interference (RNAi) therapies, immune-based treatments and capsid assembly inhibitors, which target different aspects of the virus and the body’s response to infection. The company’s investigational portfolio includes imdusiran, an RNAi therapeutic designed to reduce hepatitis B surface antigen, as well as other HBV drug candidates at various stages of development.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
